237 related articles for article (PubMed ID: 28091751)
21. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
Antonini A; Fung VS; Boyd JT; Slevin JT; Hall C; Chatamra K; Eaton S; Benesh JA
Mov Disord; 2016 Apr; 31(4):530-7. PubMed ID: 26817533
[TBL] [Abstract][Full Text] [Related]
22. Levodopa-related wearing-off in Parkinson's disease: identification and management.
Pahwa R; Lyons KE
Curr Med Res Opin; 2009 Apr; 25(4):841-9. PubMed ID: 19228103
[TBL] [Abstract][Full Text] [Related]
23. Balancing short-term symptom control and long-term functional outcomes in patients with Parkinson's disease.
Tetrud JW
CNS Spectr; 2007 Apr; 12(4):275-86. PubMed ID: 17426665
[TBL] [Abstract][Full Text] [Related]
24. Parkinson's disease related dyskinesia in a Tanzanian population.
Dotchin CL; Gray WK; Dewhurst F; Massawe J; Chaote P; Walker RW
Parkinsonism Relat Disord; 2015 Sep; 21(9):1109-10. PubMed ID: 26173703
[No Abstract] [Full Text] [Related]
25. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
[TBL] [Abstract][Full Text] [Related]
26. Parkinson's disease--levodopa complications.
King DB
Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S13-20. PubMed ID: 10451755
[TBL] [Abstract][Full Text] [Related]
27. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
Jankovic J; Stacy M
CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
[TBL] [Abstract][Full Text] [Related]
28. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
Maurel F; Lilliu H; Le Pen C
Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
[TBL] [Abstract][Full Text] [Related]
29. Levodopa-induced dyskinesia: clinical features, incidence, and risk factors.
Tran TN; Vo TNN; Frei K; Truong DD
J Neural Transm (Vienna); 2018 Aug; 125(8):1109-1117. PubMed ID: 29971495
[TBL] [Abstract][Full Text] [Related]
30. Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease.
Hashim HZ; Norlinah MI; Nafisah WY; Tan HJ; Raymond AA; Tamil AM
Int J Neurosci; 2014 Mar; 124(3):187-91. PubMed ID: 23952588
[TBL] [Abstract][Full Text] [Related]
31. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
Manson AJ; Turner K; Lees AJ
Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.
Durif F; Devaux I; Pere JJ; Delumeau JC; Bourdeix I;
Eur Neurol; 2001; 45(2):111-8. PubMed ID: 11244274
[TBL] [Abstract][Full Text] [Related]
33. Zotepine reversibly induces akinesia and rigidity in Parkinson's disease patients with resting tremor or drug-induced psychosis.
Arnold G; Trenkwalder C; Schwarz J; Oertel WH
Mov Disord; 1994 Mar; 9(2):238-40. PubMed ID: 7910949
[No Abstract] [Full Text] [Related]
34. Early morning off-medication dyskinesias, dystonia, and choreic subtypes.
Cubo E; Gracies JM; Benabou R; Olanow CW; Raman R; Leurgans S; Goetz CG
Arch Neurol; 2001 Sep; 58(9):1379-82. PubMed ID: 11559308
[TBL] [Abstract][Full Text] [Related]
35. [Incidence and determinants of levodopa-induced dyskinesia in a retrospective cohort of Mexican patients with Parkinson's disease].
Cervantes-Arriaga A; Rodríguez-Violante M; Salmerón-Mercado M; Calleja-Castillo J; Corona T; Yescas P; Alonso-Vilatela E
Rev Invest Clin; 2012; 64(3):220-6. PubMed ID: 23045943
[TBL] [Abstract][Full Text] [Related]
36. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF
Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335
[TBL] [Abstract][Full Text] [Related]
37. Levodopa in the treatment of Parkinson's disease: an old drug still going strong.
Poewe W; Antonini A; Zijlmans JC; Burkhard PR; Vingerhoets F
Clin Interv Aging; 2010 Sep; 5():229-38. PubMed ID: 20852670
[TBL] [Abstract][Full Text] [Related]
38. Predictors of motor complications in early Parkinson's disease: A prospective cohort study.
Kelly MJ; Lawton MA; Baig F; Ruffmann C; Barber TR; Lo C; Klein JC; Ben-Shlomo Y; Hu MT
Mov Disord; 2019 Aug; 34(8):1174-1183. PubMed ID: 31283854
[TBL] [Abstract][Full Text] [Related]
39. Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients.
Katayama Y; Kasai M; Oshima H; Fukaya C; Yamamoto T; Ogawa K; Mizutani T
J Neurosurg; 2001 Aug; 95(2):213-21. PubMed ID: 11780890
[TBL] [Abstract][Full Text] [Related]
40. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
Fox SH; Metman LV; Nutt JG; Brodsky M; Factor SA; Lang AE; Pope LE; Knowles N; Siffert J
Mov Disord; 2017 Jun; 32(6):893-903. PubMed ID: 28370447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
